Dose-finding study of rivaroxaban in hemodialysis patients

American Journal of Kidney Diseases

Volumn 66, Issue 1, 2015, Pages 91-98

  De Vriese, An S ^a   Caluwé, Rogier ^b   Bailleul, Els ^b   De Bacquer, Dirk ^c   Borrey, Daniëlle ^d   Van Vlem, Bruno ^b   Vandecasteele, Stefaan J ^a   Emmerechts, Jan ^d  

^a Department of Internal Medicine   (Belgium)

^b OLV HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d NONE   (Belgium)

Author keywords

anti FXa activity; anticoagulant; area under the curve (AUC); atrial fibrillation; dose adjustment; dose finding; dosing guideline; end stage renal disease (ESRD); Hemodialysis; pharmacodynamics; pharmacokinetics; rivaroxaban; stroke

Indexed keywords

RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; OUTCOME ASSESSMENT; PROTHROMBIN TIME; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; ATRIAL FIBRILLATION; BLEEDING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; DRUG MONITORING; HALF LIFE TIME; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; THROMBOEMBOLISM; THROMBOPHILIA;

ADMINISTRATION, ORAL; AREA UNDER CURVE; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA INHIBITORS; FEMALE; HALF-LIFE; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MORPHOLINES; RENAL DIALYSIS; THIOPHENES; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 84937521722     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.01.022     Document Type: Article

References (24)

1. W.C. Winkelmayer, A.R. Patrick, J. Liu, M.A. Brookhart, and S. Setoguchi The increasing prevalence of atrial fibrillation among hemodialysis patients J Am Soc Nephrol 22 2 2011 349 357
2. J. Kooiman, N. van Rein, B. Spaans, and et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease PLoS One 9 5 2014 e94420
3. M. Wieloch, K.M. Jönsson, A. Själander, G.Y.H. Lip, N. Eriksson, and P.J. Svensson Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin Thromb Res 131 6 2013 481 486
4. Y.T. Zhang, and Z.Y. Tang Research progress of warfarin-associated vascular calcification and its possible therapy J Cardiovasc Pharmacol 63 1 2014 76 82
5. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Clin Pharmacokinet 53 1 2014 1 16
6. W. Mueck, S. Schwers, and J. Stampfuss Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring Thromb J 11 1 2013 10
7. J. Stampfuss, D. Kubitza, M. Becka, and W. Mueck The effect of food on the absorption and pharmacokinetics of rivaroxaban Int J Clin Pharmacol Ther 51 7 2013 549 561
8. C. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs and humans Drug Metab Dispos 37 5 2009 1056 1064
9. D. Kubitza, M. Becka, W. Mueck, and et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor Br J Clin Pharmacol 70 5 2010 703 712
10. Y.B. Cao, J.D. Zhang, H. Shen, and Y.Y. Jiang Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Eur J Clin Pharmacol 66 11 2010 1099 1108
11. R. Bauersachs, S.D. Berkowitz, B. Brenner, and et al. Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 26 2010 2499 2510
12. EINSTEIN-PE Investigators H.R. Büller, M.H. Prins, A.W. Lensin, and et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 14 2012 1287 1297
13. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
14. K.A. Fox, J.P. Piccini, D. Wojdyla, and et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J 32 19 2011 2387 2394
15. Bayer Pharma AG. Xarelto (rivaroxaban) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000944/WC500057108.pdf. Accessed October 23, 2014.
16. Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202439s001lbl.pdf Accessed October 23, 2014.
17. J. Douxfils, A. Tamigniau, B. Chatelain, and et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban Thromb Haemost 110 4 2013 723 731
18. F. Peters, O. Drummer, and F. Musshoff Validation of new methods Forensic Sci Int 165 2-3 2007 216 224
19. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 21 2014 e1 e76
20. P. Sardar, S. Chatterjee, E. Herzog, R. Nairooz, D. Mukherjee, and J.L. Halperin Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials Can J Cardiol 30 8 2014 888 897
21. M.M. Samama, G. Contant, T.E. Spiro, and et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial Clin Appl Thromb Hemost 18 2 2012 150 158
22. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 104 6 2010 1263 1271
23. M.N. Lauw, M. Coppens, and J.W. Eikelboom Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent Can J Cardiol 30 4 2014 381 384
24. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, and et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 14 2011 1573 1579